Potential First-in-Class, Liver-Selective Glucokinase Activator HIGH POINT, N.C. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes at
HIGH POINT, N.C. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) announced the appointment of Edward P. Taibi , Executive Vice President of MacAndrews & Forbes Incorporated (“MacAndrews”), to the vTv Board of Directors. Effective August 31, 2020 , Mr.
HIGH POINT, N.C. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2020 , and provided an update on the progress of its clinical programs. “Building on the successful phase 2 study completed earlier this
HIGH POINT, N.C. , July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc . (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International Conference (AAIC), held virtually, July 27–31, 2020. The poster presentation will highlight additional
- Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or diabetic ketoacidosis (DKA) - HIGH POINT, N.C. , June 13, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today made two presentations at the
HIGH POINT, N.C. , May 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented virtually at the American Diabetes Association’s 80th
HIGH POINT, N.C. , May 22, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-only meeting that will be held via live audio webcast due to the public health and safety concerns
HIGH POINT, N.C. , May 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2020 , and provided an update on recent clinical achievements. “In spite of the challenges presented by the COVID-19 pandemic, we are
Company Announced Positive Results from Its Phase 2 Type 1 Diabetes Trial Showing that TTP399 Lowered HbA1C, Decreased the Use of Insulin for Patients and Increased Time in Range HIGH POINT, N.C. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.
- TTP399, a novel glucokinase activator, achieves primary objective of a statistically significant reduction in HbA1c, without increases in hypoglycemia or ketoacidosis - Company to host investor conference call today at 8:30 a.m. ET HIGH POINT, N.C. , Feb.